13-17 September 2010
If you think all cancers are the same, you are wrong! Every type of cancer travels on its own path. While some seem to move at the speed of light, others are just wandering about. Usually, prostate cancer takes it very easy. Often it grows so slowly that it is not even discovered during a man’s lifetime. Prostate cancer cells seem to develop quite early in life. By the time you are 40, you have a 30% chance that your prostate may harbour cancer cells. By age 60, the chances are roughly 50%. Should you be worried? Not necessarily.
In many men cancer
cells will not continue to develop into a harmful
disease. Moreover, your lifetime risk of dying from prostate cancer is only
about 3%. On the other hand, are you willing to take a chance? This is where
screening plays a role. Wouldn’t it be smarter to detect in time and reduce
your prostate cancer risk before it even gives you any symptoms? We at
Europa Uomo invite you to visit
www.urologyweek.org
"Forum
Against Cancer Europe" (FACE) launched in the European Parliament, supported
by more than 50 MEPs
On 23 June a new initiative of the European Cancer Patient Coalition (ECPC) entitled Forum Against Cancer Europe (FACE) was successfully launched at the European Parliament. The Forum Against Can-cer Europe" (FACE) has been set up to continue the successful dialogue of the European cancer patient community with European Parliamentarians, Commission and all concerned stakeholders. It was launched with a workshop entitled "More Cancer Research Needed in the EU: Cancer Affects Almost Every Family". The meeting was hosted by MEP Marisa Matias and featured high level speakers from the European Parliament, EU Commission, research community and patient groups. Already 54 MEPs are supportive of the new FACE initiative. (...)
Read all the PRESS RELEASE here.
Sign the Proactive Prostates Initiative Call to Action
We call upon governments, public health institutions, health care workers, and members of civil society to join this Call to Action. Together we must work towards ensuring that all men have access to the best possible information and treatment.
Sign in and more information at Europa Uomo News.
ALSYMPCA
trial
- Alpharadin (Radium 223)
Phase II Results and Phase III Study of Alpharadin (Radiu m-223) in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)
This study is currently recruiting participants.
Please see more details at Medical News and Reports.
Genome
Research of the Prostate Cancer
German Cancer Research Center Heidelberg, University Clinic and Martini Clinic Hamburg start genome research of the prostate cancer within the International Cancer Genome Consortium (ICGC).
On the 22nd of June the German Federal Department for Education and Research approved and resourced the analysis oft the entire genomic DNA sequences of at least 500 PCA (and matched non-tumorous DNA) of young men (≤ 50y). Genomic structural variations will be determined using large-paired-end sequencing of the same samples. Complementary molecular analyses (mRNA, miRNA and epigenomic profiling) in subsets of these tumors will be conducted.
This project fits into the ICGC structure where as of March 2010 an international consortium (Canada, UK, France) was organized focussing on prostate cancers from all ages.
The comparison of data on specific genomic patterns of early onset prostate cancer from Germany with the data from the international consortium will enable a comprehensive description of genetic and epigenetic (as well as hereditary) changes in prostate cancer development and progression.
Goals of the ICGC are -
Coordinate the generation of comprehensive catalogues of genomic abnormalities (somatic mutations) in tumors in 50 different cancer types and/or subtypes which are of clinical and societal importance across the globe. Ensure high quality by defining the catalogue for each tumor type or subtype to include the full range of somatic mutations including single-nucleotide variants, insertions, deletions, copy number changes, translocations and other chromosomal rearrangements.
1. Generate complementary catalogues of transcriptomic and epigenomic datasets from the same tumors.
2. Make the data available to the entire research community as rapidly as possible, and with minimal restrictions, to accelerate research into the causes and control of cancer.
More information about the International Cancer Genome Consortium are available at www.icgc.org/icgc/goals-structure-policies-guidelines/introduction
Patient
Guidebook For The Diagnosis and Treatment of Advanced Prostate Cancer
The patient guidebooks for the diagnosis and treatment of the locally confined and for the advanced prostate cancer are now available in Germany. Both patient guidebooks are based upon the S3 interdisciplinary medical guidelines of the highest evidence level, which was published during September of 2009. Authors of the patient guidebooks are physicians and 3 patient advocates from the German Prostate Cancer Support Organization, BPS. They were also members of the S3 medical guideline commission.
The patient guide book for the locally confined prostate cancer may be downloaded at www.aezq.de/edocs/pdf/info/pl-prostatakarzinom
and for the advanced prostate cancer at www.aezq.de/edocs/pdf/info/pl-pca-II.pdf
| Disclaimer - |
Europa-Uomo.org is intended to be for information use only and not designed to provide medical advice or professional services. The information provided throughout this website is not a substitute for medical care and should not be used for diagnosing or treating prostate cancer. If you have, or suspect you may have, a health problem you should consult a doctor. |